Outcome
    Moderate Evidence

    Vitamin D for Mood Stabilization

    Observational links between low vitamin D and depression are strong, but randomised trials in people who are not deficient have mostly been negative, including the large VITAL-DEP trial.

    Overview

    Observational links between low vitamin D and depression are strong, but randomised trials in people who are not deficient have mostly been negative, including the large VITAL-DEP trial.

    Verdict

    Mixed evidence

    How It Works

    Vitamin D receptors are present in the prefrontal cortex, hippocampus and substantia nigra, and calcitriol influences the expression of tyrosine hydroxylase, the rate-limiting enzyme in dopamine and noradrenaline synthesis. It also regulates neurotrophic factors and modulates neuroinflammation. The difficulty is direction of causation. Depression reduces outdoor activity and sunlight exposure and worsens diet, all of which lower 25(OH)D independently, so the consistent cross-sectional association can be produced without vitamin D having any causal role in mood.

    Dosing & Protocol

    Typical dose

    Recommended dose
    Studied at 2,000 IU/day and above; no mood-stabilising effect has been demonstrated
    Expected timeframe
    Not established

    Protocol

    form
    Vitamin D3 (cholecalciferol) with a fat-containing meal
    duration
    VITAL-DEP ran a median of 5 years
    co factor
    Evidence is mixed and, for mood stabilisation specifically, absent. Vitamin D receptors exist in mood-relevant brain regions, and observational studies link low 25(OH)D to depression and to bipolar disorder, but the interventional evidence is negative: VITAL-DEP randomised over 18,000 adults to 2,000 IU/day and found no effect on depression incidence or mood scores. No adequately powered trial has tested vitamin D for mood stabilisation in bipolar disorder or cyclothymia, and mood stabilisation in the clinical sense means preventing manic and depressive episodes - something only established mood stabilisers have been shown to do.
    titration
    Not applicable for this indication; 4,000 IU/day is the tolerable upper intake level
    starting dose
    Not established for mood stabilisation. VITAL-DEP used 2,000 IU/day; smaller trials used up to 4,000 IU/day

    Evidence

    What the studies say

    The VITAL-DEP ancillary study randomised over 18,000 adults to 2000 IU of vitamin D3 daily or placebo for a median of five years and found no difference in depression incidence or in mood scores. Several smaller trials in vitamin D deficient participants have reported improvement in depressive symptoms, and meta-analyses restricted to deficient populations find a small positive effect. Taken together, the literature supports correcting documented deficiency rather than supplementing for mood in people who are replete. Vitamin D is not a treatment for depression, and persistent low mood warrants clinical assessment. Seasonal mood change specifically has stronger evidence for light therapy than for supplementation.

    No studies are yet linked to both Vitamin D and Mood Stabilization.

    Safety

    Caveats

    Mood stabilisation is a specific psychiatric concept - preventing recurrence of manic, hypomanic and depressive episodes - and the treatments that achieve it are lithium, valproate, lamotrigine, quetiapine and related agents, all requiring specialist prescribing and monitoring. No supplement does this, and stopping or reducing a mood stabiliser risks relapse, hospitalisation and suicide. Anyone experiencing periods of elevated mood, reduced sleep need, racing thoughts, impulsive spending or risk-taking alternating with depression needs psychiatric assessment, and thoughts of self-harm need urgent help. Correcting documented vitamin D deficiency is fine alongside treatment. Safety of vitamin D: the tolerable upper intake level is 4,000 IU/day, and sustained higher doses cause hypercalcaemia with nausea, vomiting, thirst, confusion, mood and cognitive changes, kidney stones and kidney injury. Importantly, thiazide diuretics raise hypercalcaemia risk, and lithium also raises calcium and can cause hyperparathyroidism, so high-dose vitamin D alongside lithium needs medical supervision and calcium monitoring. Corticosteroids, orlistat, cholestyramine and some anticonvulsants lower vitamin D levels. Supplementation is hazardous in sarcoidosis, tuberculosis, lymphoma and hyperparathyroidism. In pregnancy 400-1,000 IU/day is standard.

    Less likely to help if

    Everyone seeking mood stabilisation - no trial supports this use.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.